cyrilzakka/clinical-trials huggingface dataset:
The Role of Oxytocin in the Perception of Faces

The main objective of this project is to study whether intranasal oxytocin (OT) affects how young adults perceive and attend to infant and adult faces. Based on existing research the investigators predict that oxytocin will facilitate the allocation of attentional resources on infant faces (compared to adult faces). The investigators also predict that oxytocin will enhance the activity of reward neural-networks associated with the perception of infant faces. The behavioral effects of OT (visual attention and face recognition) will be measured with eye-tracking while participants look at photographs of adult and infant faces. Neurological effects (the activity of emotion and reward networks) will be measured with functional Magnetic Resonance Imaging (fMRI) while participants look at infant faces on a computer screen.


Eligibility Criteria:
Inclusion Criteria:

* Healthy Volunteers
* Norma or corrected to norma vision
* Participants are non parents
* Able to provide written informed consent and to comply with all study procedures

Exclusion Criteria:

* Dementia or severe cognitive disorders
* Endocrine disease or malignancy
* Nasal obstruction or upper-respiratory tract infection
* Current or previous psychiatric disorder
* Current or previous use of psychoactive drugs
* Alcoholism or substance abuse
* History of seizures
* Neurological Disorder
* Previous head trauma
* Hypertension
* Cardiovascular Disease
* Claustrophobia
* ferrous metal in any part of the body
Sexual Functioning Study With Antidepressants

Effects of two depression medication on sexual functioning

A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/day) and Extended-release Venlafaxine (EFFEXOR XR, 75-225 mg/day) in Subjects with Major Depressive Disorder

Eligibility Criteria:
Inclusion criteria:

* Primary diagnosis of Major Depressive Disorder (MDD)
* must have met DSM-IV criteria for current major depressive episode for at least 8 weeks but no long than 2 years.
* HAM-D17 total score of \>17 at screening and baseline.
* Severity of illness score of \>4 at screening and baseline.
* Willing to discuss sexual functioning with investigator or designee.
* Sexual activity that leads to orgasm at least every 2 weeks.

Exclusion Criteria:

* Past or current DSM-IV diagnosis of Bipolar Disorder I or II, schizophrenia or another psychotic disorder(s).
* Primary DSM-IV diagnosis or received treatment for Panic Disorder, Obsessive Compulsive Disorder or Post Stress Disorder within previous 12 months.
* Poses a homicidal or serious suicidal risk, have made an attempt within months prior to screening or who has ever been homicidal.
* Myocardial infarction with 1 year of screening.
* Taken ibupropion hydrochloride or venlafaxine in the last 6 months.
* Positive urine test for illicit drug use or alcohol or substance abuse within the past 12 months.
* Psychotherapy within 3 months.
* Pregnant.
* Electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior of screening.
* ECG or clinical evidence of atrial or ventricular hypertrophy.
DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients

A Multicenter, Open label, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen DIA:CONN P8 in patients with Type 1, Type 2 or Pancreatogenic Diabetes Mellitus under Multiple Dose Insulin Therapy

\[Blind CGM Period\] All eligible participants who voluntarily provide informed consent to participate in this clinical trial and are determined suitable for trial inclusion/exclusion criteria undergo a blind CGM before the baseline visit (randomization). During this period, every subjects is provided with two DIA:CONN P8 devices for continuous glucose monitoring (CGM), basal insulin, and bolus insulin administration.

Throughout this period, subjects receive training on fundamental insulin pen usage and CGM operation. They use the DIA:CONN P8 specifically for insulin dosage entry and administration, functioning similarly to a conventional insulin pen, only utilizing the injection and injection recording function.

Insulin injection dosages and timing (time stamps) recorded on the DIA:CONN P8 and the participant's blood glucose data logged in the CGM app are collected.

\[Application Period\] The subject allocated to the intervention or control group through randomization will visit hospital maximun 5 times during the 12-week application period, including the baseline visit, in the following process.

1. Treatment Group: For the treatment group, education sessions will be conducted during the baseline visit on carb counting and bolus calculator methods, installation, and usage instructions for DIA:CONN P8 and DIA:CONN app, as well as CGM and CGM app.
2. Control Group: The control group will receive education on insulin pen and CGM usage, maintaining their conventional multiple dose insulin therapy while implementing CGM.

Eligibility Criteria:
Inclusion Criteria:

1. Age between 19 and 75 years old.
2. Confirmed diagnosis of Type 1 or Type 2 diabetes or post-pancreatectomy(total or partial) diabetes at least 1 year prior to screening.
3. Currently using multiple dose insulin therapy at least 3 months prior to screening, regardless of Continuous Glucose Monitoring(CGM) usage.
4. HbA1c levels between 7.5% and 12.0% at screening.

Exclusion Criteria:

1. Who have administered medications affecting glucose metabolism within 3 months before screening(e.g., corticosteroids, immunosuppressants) (Candidate with stable, ongoing dosage for over 6 months before screening are exempted from this criterion).
2. Diagnosed with clinically significant cardiovascular disease within 6 months prior to screening.
3. Exhibiting an estimated glomerular filtration rate(eGFR)\<15 mL/min at the screening.
4. Unable to engage in study education due to severe systemic disorders(e.g., end-stage renal failure requiring dialysis, liver cirrhosis of Child-Pugh Class C or higher, etc)
5. Participants with severe diabetic complications(e.g., diabetic foot, diabetic retinopathy, etc)
6. Pregnant or lactating women
Promoting Vegetable Intake in Preschool Aged Children

The aim of this cluster randomised control trial is to test the efficacy of a repeated taste exposure intervention, a nutritional educational intervention and combination of both to increase intake of an unfamiliar vegetable in preschool aged children (aged 3-5 years).

The aim of this study is to test the efficacy of a repeated taste exposure intervention, a nutritional educational intervention and combination of both to increase intake of an unfamiliar vegetable in preschool aged children (aged 3-5 years). In particular the study will assess whether these strategies are effective to encourage intake of an unfamiliar vegetable in children who are fussy eaters or going through the food neophobia phase. The effectiveness of these interventions will also be observed overtime at 3 and 6 months post intervention.

Nurseries will be randomised into one of four conditions over the 12 week intervention period; these include educational intervention only, taste exposures only, taste exposures and educational intervention or no intervention (control group). All children will be offered an unfamiliar vegetable prior to the intervention and after the intervention to evaluate changes in intake of the unfamiliar vegetable. The repeated taste exposure groups will be offered the novel vegetable repeatedly (1 exposure per week) over the 12 week period. For the educational intervention nursery staff will be advised to deliver two components of an existing PhunkyFoods educational programme over the same period.

Parents will be asked some general demographic questions, child food behaviour questions and questions about their feeding practices. Finally nursery staff will be requested to provide feedback to evaluate intervention feasibility, barriers and efficacy.

It is predicted that children's intake of the unfamiliar vegetable will vary by intervention. The primary hypothesis to be tested is that children who receive the repeated taste exposures are more likely to increase their intake of the unfamiliar vegetable compared to those in educational only or control conditions. The second hypothesis is that repeated taste exposures will increase intake of an unfamiliar vegetable in fussy eaters more than education.

Eligibility Criteria:
Inclusion Criteria:

* 2 to 5 years old
* Attends nursery on selected test day

Exclusion Criteria:

* Relevant food allergy (mooli / radish)
* Medical condition which would prevent them from eating the test vegetable
Thoracic Sympathetic Ganglion Block With Botulinum Toxin Type A

Thoracic sympathetic ganglion block is a percutaneous procedure that paralyzes the action of sympathetic nerves transiently by injecting a local anesthetic around the ganglion. It is performed to diagnose and treat sympathetically maintained pain in phantom limb pain or complex reginal pain syndrome patient. The temperature of the affected arm is often lower than that of the opposite side. As a result of the procedure, the patient may experience sympathetic pain relief, such as coldness, stinging, numbness of the upper extremity. If the procedure does not last long, repetitive block or chemical neurolysis or radiofrequency thermocoagulation for the sympathetic ganglion is performed.

However, even though in rare cases, chemical neurolysis is known to cause permanent plexus injury radiofrequency thermocoagulation is known to be less successful than chemical neurolysis because it is difficult to identify and stimulate the exact location of the ganglion. Therefore, it is expected that there will be a benefit to the patients if there is a procedure with long-lasting and avoiding injury.

Recently, it has been reported that botulinum toxin (BTX) has been successfully used for the treatment of pain disorders. BTX plays a role with blocking the secretion of acetylcholine from the cholinergic nerve endings. Therefore, the use of BTX is expected to prolong the effect of neural blockade because pre-ganglia sympathetic nerves are cholinergic. It is also known that the action of BTX is not permanent and BTX does not exhibit cytotoxicity or neurotoxicity. Therefore, Botulinum toxin type A (BTA) is recommended for the treatment of migraine, myofascial pain syndrome, and neuropathic pain accompanied by allodynia. This study would like show whether thoracic sympathetic ganglion block using BTA has a longer duration than conventional local anesthesia by using prospective randomized, double-blind, parallel group, and comparative clinical trials.


Eligibility Criteria:
Inclusion Criteria:

1. aged 19-80 years
2. Diagnosed with a complex regional pain syndrome (type 1 or 2) in unilateral upper extremity
3. 11-point numerical-rating-scale (NRS) pain score of 4 or higher in upper extremity
4. Temperature increase at diagnostic thoracic sympathetic ganglion block
5. Patients taking medication stably (without change in dosage/recipe) for more than 4 weeks prior to administration

Exclusion Criteria:

1. Refusal of the patient
2. Vascular disease at upper extremity
3. previous thoracic sympathetic neurolysis (thermocoagulation, chemical neurolysis)
4. coagulopathy
5. systemic infection or local infection at thoracic puncture site
6. significant deformity at thoracic spine
7. neoplasm
8. known allergic reaction with amide type local anesthetics
9. cognitive dysfunction (not understanding of numerical-rating-scale)
10. known allergic reaction with botulinum toxin
11. pregnant or feeding women
12. If the patient has participated in another clinical trial within 30 days before screening, or if passed no longer than 5-fold half-life of the clinical trial drug of the participating clinical trial
The Cooling And Surviving Septic Shock Study (CASS)

Septic shock is in critically ill patients is a condition associated with a high rate of organ failure and hereto attributable mortality \~45-55% Hypothesis: Mild Induced Hypothermia reduces the mortality of critically ill patients with septic shock by reducing organ metabolism, counteracting on microcirculatory thrombosis, genetically downregulating tissue apoptosis and by reducing bacterial growth rate and toxin production.

Septic shock is an acute life-threatening condition, with great organ damage for every hour. The patients have a high risk of dying and therefore rapid treatment is of crucial importance for survival of the patients.

Septic shock is mainly due to a collapse in the blood circulation (the capillary system) due to blockage by blood cells - a process initiated by substances from the cells of the immune system via activation of coagulation. The normal function of the smallest blood vessels is to transport oxygen, nutrients and drugs to organs and tissues, and lead waste products away. While the offer of oxygen and nutrients to the organs decreases, the consumption of oxygen and nutrients increases due to fever and immune reactions.

When the capillary system collapses, the organs and tissues suffer, and various forms of cell death in the organs begins including "programmed cell death" ("apoptosis"). This leads to organ damage, for example brain damage or kidney damage and ultimately to multiple organ dysfunction which is the direct cause of the patient dies.

Mild induced hypothermia (cooling to 32 0C-34 0C) affects at least 5 core areas in the pathophysiology of septic shock: 1) inhibition of inflammation 2) inhibition of apoptosis ("programmed cell death"), 3) antithrombotic, 4) decreases the metabolism and 5) inhibits bacterial growth and production of toxins.

Eligibility Criteria:
Inclusion Criteria:

1. Aged \> 50 years of age.
2. Severe sepsis /septic shock = SIRS + suspected infection+hypotension Mean Arterial Blood Pressure (MAP) \<70 mmHg,
3. Admitted to the participating intensive care units (ICU)
4. Indication for intubation
5. Possibility of inclusion within 6 hours after septic shock/severe sepsis is diagnosed in the ICU. Patients admitted with septic shock/severe sepsis should be included within 6 hours after admission. If a patient is not included within this period, that patient cannot be included within the same hospitalization.
6. The patient must have an expected stay in the ICU of more than 24 hours. Anticipated death within 24 hours after admission to the ICU does not exclude participation; however no decision of reduction of treatment level must have been taken. During this time period, probability that the patient is discharged to a floor department must not be likely (\<10% probability).

Exclusion Criteria:

1. Patients are pregnant or breast feeding
2. The findings of the initial screening, shows that the patient has a bleeding disorder and/or the patient has an uncontrollable bleeding and /or surgery within the last 24 hours
3. Persons who are detained under the Act on the use of coercion in psychiatry
Effects of Pain Neuroscience Education and Virtual Reality in Patients with Chronic Low Back Pain

The objective of our study is to evaluate the effects of a therapeutic intervention including

1-hour of pain neuroscience education session, 30-minutes of exposure to exercise with virtual realit and therapeutic exercise in patients with chronic low back pain.

Chronic low back pain is the world's leading cause of years of life lived with disability. Negative thoughts and beliefs about pain experienced can lead to pain avoidance behaviours. Fear of movement is a common behaviour in this type of patients and is associated with avoidance of exercise. Virtual reality is a powerful distraction technique as it directs the patient's attention to an external stimulus rather than pain or body movement. Therefore, it can be beneficial to avoid some pain-related problems, such as kinesiophobia and inactivity. Moreover, pain neuroscience education aim to reconceptualise pain perceptions, beliefs, and avoidance behaviours. Then, the use of these interventions may be beneficial in the treatment of patients with chronic low back pain.

The objective of this study is to evaluate the effects of a therapeutic intervention using pain neuroscience education and virtual reality in patients with chronic low back pain.

Eligibility Criteria:
Inclusion Criteria:

* Chronic musculoskeletal pain (≥ 3 months)
* Adults (≥ 18 years and less than 65 years)
* Score ≤18 points in Pain Detect Scale
* Wish to participate in the study and sign the informed consent
* Speaking Spanish

Exclusion Criteria:

* Neuropathic pain (score ≥18 in Pain Detect Scale)
* Physical or psychological pathology of any kind that imply an inability to understand the necessary instructions to carry out the study will be excluded.
A Method to Optimize Mecanical In-exsufflation in Neuromuscular Diseases

The investigators want to demonstrate that there is an optimal expiratory pressure when using mecanical in-exsufflation for each patient in neuromuscular disease. This compromise is between the need to generate a high pressure difference between alveoli and the mouth and the need to avoide and superior airways collapsus.

he investigators want to demonstrate that there is an optimal expiratory pressure when using mecanical in-exsufflation for each patient in neuromuscular disease. This compromise is between the need to generate a high pressure difference between alveoli and the mouth and the need to avoide and superior airways collapsus.

Eligibility Criteria:
Inclusion Criteria:

* man or female age18 years
* neuromuscular disease
* coughassist adaptation treatment
* peak cough flow\<270liter/minute

Exclusion Criteria:

* acute organ failure
* insufflation contrindication
* pregnant women/no affiliation to a social security scheme
* plan of legal protection
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.


Eligibility Criteria:
Inclusion criteria Participants with unresectable advanced/recurrent ALK fusion gene-positive non-small cell lung cancer.

Exclusion criteria Participants who has a history of hypersensitivity to any component of birigatinib.
The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul

COVID-19, which emerged in China in December 2019, has become a pandemic with its spread to many countries of the world. The aim of this multi-centered study is to guide for the approach, organization, diagnosis and treatment of the patients admitted due to trauma to emergency department during the pandemic period.

COVID-19, which emerged in China in December 2019, has become a pandemic with its spread to many countries of the world. The investigators hypothesize that since the number of hospital applications expected to be decreased due to trauma during the COVID-19 period, the level of hospital trauma applications changed. Thus, the aim of this multi-centered study is to guide for the approach, organization, diagnosis and treatment of the patients admitted due to trauma to emergency department during the pandemic period.

Eligibility Criteria:
Inclusion Criteria:

* accepted to participate with an informed consent
* trauma patients who admitted to the study centers

Exclusion Criteria:

* lack of informed consent
* lack of data
High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis

Objectives:

1. To evaluate endurance time during cardiopulmonary exercise test (CPET) performance comparing standard oxygen therapy to high-flow nasal cannula (HFNC) oxygen therapy in subjects with idiopathic pulmonary fibrosis (IPF) with exertional desaturation.
2. To assess oxygenation level (peripheral and muscular) as well as dyspnea and fatigue during exercise in IPF subjects with exertional desaturation using oxygen supplementation with HFNC compared with standard oxygen supplementation.

Method: multicenter crossover clinical trial. Patients with IPF presenting oxygen desaturation during the six-minute walking test (6MWT) (SpO2 mean ≤ 85%) will be included consecutively . Each subject evaluated will perform initially an incremental CPET to evaluate the patient's maximum exercise capacity. Supplemental oxygen will be applied to maintain SpO2 \>85% with a Venturi mask. Maximum exercise capacity and the appropriate final oxygen inspiratory fraction (FiO2) needed for the following tests will be determined.

Posteriorly each patient will perform two constant load CPET (at 75% of the maximum workload achieved with the incremental CPET); one with standard oxygen therapy and the other one with HFNC oxygen therapy. Endurance time, dyspnea and leg fatigue and oxygen saturation (peripheral and muscular) will be recorded.

Evaluation measures: Endurance time, dyspnea and leg fatigue (Borg scale), and oxygen saturation.


Eligibility Criteria:
Inclusion Criteria:

* Subjects with IPF diagnosis according to the 2018 international consensus guidelines
* Mean SpO2 ≤ 85% during the 6MWT performed under room air conditions

Exclusion Criteria:

* Fibrotic interstitial lung diseases other than IPF
* Chronic obstructive pulmonary disease (COPD)
* Inability to perform a complete CPET due to osteo-articular or cognitive limitations
* End-stage lung disease
* Severe pulmonary hypertension
Online Information on Myofascial Pain Syndrome

The investigators aim in this study is to evaluate myofascial pain syndrome (MPS) related websites in terms of the quality and the readability of the information. Also, to identify the typologies of websites that provide high-quality information about MPS.

Introduction The reliability of information on the internet, which people use as an easy and practical solution about diseases, is very important for public health. The ivestigatior aim in this study to evaluate the quality and readability of websites related to myofascial pain syndrome.

Methods On April 4, 2020, web sites were searched on the Google search engine by using the term "myofascial pain syndrome". The typologies, quality and readability parameters of the sites were analyzed. Websites were divided into eight categories according to typology. In order to evaluate the quality, it is checked whether there is JAMA scoring system and HONcode certificate. Flesch-Kincaid grade and the Simple Measure of Gobbledygook was used to evaluate readability.

Eligibility Criteria:
Inclusion Criteria:

• The URL of the first 200 sites

Exclusion Criteria:

* The sites in languages other than English
* The sites with video and audio recording but without reading text
* The sites with access problems or requesting registration
* Subscription and the sites that do not provide information about myofascial pain syndrome
Benefits of an Oocyte Pickup Simulation Training Program

The primary objective of this study was to evaluate oocyte pick up simulation training program for teaching residents. The secondary objectives were to evaluate resident satisfaction and the overall current state of oocyte pick up training in France.

simulation workshop using PickupSim simulator. inclusion: obstetrics and gynecology residents from France simulator: 7 scenarios available

1 simulation training/resident main outcome: successful completion of the scenario (oocyte retrieval rate \>=70%) secondary outcome: time for completion, complications, satisfaction survey

Eligibility Criteria:
Inclusion Criteria:

* obstetrics and gynecology residents
* french residents

Exclusion Criteria:

* no